secwatch.observer — SEC 8-K summary
======================================

Issuer:     PharmaCyte Biotech, Inc. (PMCB)
CIK:        0001157075
Form:       8-K
Filed at:   2021-08-12T23:59:59+00:00
Accession:  0001683168-21-003431
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PharmaCyte Biotech announces Nasdaq uplisting and pricing of $15M public offering at $4.25/unit
--------------------------------------------------------------------------------

- Common stock begins trading on Nasdaq Capital Market under PMCB on August 10, 2021.
- Public offering of 3,529,412 units at $4.25 per unit (1 share + 1 warrant); gross proceeds ~$15M.
- Warrants exercisable at $4.25, immediately, expire in 5 years; pre-funded warrants also offered.
- H.C. Wainwright sole book-runner; underwriter granted 30-day option for up to 529,411 additional units.
- Executive officers and directors subject to 90-day lock-up from prospectus supplement date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157075/000168316821003431/0001683168-21-003431-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157075/000168316821003431/pharmacyte_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-21-003431

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer